Navigation Links
TGen Drug Development accompanies GPEC to BayBio2010
Date:4/6/2010

PHOENIX, Ariz. April 6, 2010 Scottsdale-based TGen Drug Development (TD2) will join the Greater Phoenix Economic Council (GPEC) this week at BayBio2010 in an effort to spur Arizona's bioscience industry.

BayBio2010 is a one-day conference April 7 in San Francisco sponsored by BayBio, an industry trade group focused on Northern California's 1,400 bioscience companies, more than any other single region in the world.

"We will showcase TD2's unique oncology solutions, including our integrated approach to guiding biopharmaceutical firms through anti-cancer drug creation, clinical trials and regulatory approvals," said Debbie Snyder, TD2's Vice President for Business Development. "TD2 holds the potential to make significant contributions to patient care, while at the same time sparking major advancements in the Phoenix-area economy."

A recent study shows that TD2 is poised to play a significant role in the expansion of Scottsdale's biomedical industry, fostering new jobs and city revenues, and prompting the creation of more related businesses. The independent economic research firm Tripp Umbach of Pittsburgh released a report in January pegging TD2's total annual economic impact on Scottsdale in 2009, including affiliated company operations, at $26 million a figure expected to grow to $239 million by 2015.

GPEC, Arizona's leading non-profit economic development organization, aims to build on Arizona's unprecedented recent growth in its bioscience industries. Public-private collaborations have created world-class biomedical research centers, including TD2's parent organization, the Phoenix-based Translational Genomic Research Institute (TGen). From 2002, when TGen began, to 2007, bioscience jobs in Arizona increased by 23 percent, compared to a national average of 11 percent.

The GPEC delegation also will include representatives from Tempe and Chandler, and the company InNexus Biotechnology Inc. The group's goal is to promote Greater Phoenix's growing bioscience industry with the intent of attracting new companies and jobs to the region.

"Arizona's bioscience industry is gaining strength with such examples as VisionGate relocating to the Valley," said Barry Broome, president and CEO of GPEC. "Greater Phoenix is recognized as a center of excellence in health care, home to world-class leadership and a hub of innovative partnerships. Companies are taking notice of the environment we are creating here."

BayBio2010 is one of nation's first bioscience conferences since last month's passage of federal health care reform legislation, the Patient Protection and Affordable Care Act, which has been touted by BayBio as "a big win" for the life science industry.

A key provision, according to BayBio, is the Therapeutic Discovery Project Tax Credit, which will provide $1 billion over two years to help companies with 250 or fewer employees offset a portion of the costs for therapeutic development activities, including hiring scientists and conducting clinical studies.

BayBio2010 will examine the fundamental questions of who pays for biotech innovation and why, and focus on how the current financial environment and new sources of capital could affect business models, development and commercialization strategies. The conference also will review new trends in public markets, venture investment, mergers and acquisitions, and life sciences research and development.


'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related biology news :

1. Gender, coupled with diabetes, affects vascular disease development
2. New target for anti-flu drug development
3. Selexis Announces Advanced Approach to Maximize Power of Genetic Elements for Rapid Development of High Performance Cell Lines
4. KAUST and American University in Cairo to collaborate on research and academic development
5. Old developmental pathways spawn revolutionary evolutionary changes
6. NIST announces 56 new awards for innovative technology research and development
7. Progress Against Malaria: Developments on the Horizon
8. Flu vaccine in painless skin patches under development at Emory, Georgia Tech with NIH grants
9. Biopharmaceutical infrastructure key to lower drug development costs
10. Study identifies pathway required for normal reproductive development
11. 200 journals join in theme issues on poverty and human development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2016)... 2016   The Weather Company , an IBM Business ... industry-first capability in which consumers will be able to interact ... questions via voice or text and receive relevant information about ... Marketers have long sought an advertising solution that can ... personal, relevant and valuable; and can scale across millions of ...
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC , ... announced the opening of an IoT Center of Excellence ... and expand the development of embedded iris biometric applications. ... level of convenience and security with unmatched biometric accuracy, ... identity aside from DNA. EyeLock,s platform uses video technology ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, ... launch of their brand, UP4™ Probiotics, into Target stores nationwide. The company, which ... to add Target to its list of well-respected retailers. This list includes such ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. ... test has received AOAC Research Institute approval 061601. , “This is another AOAC-RI ... stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate ...
(Date:6/23/2016)... ... , ... STACS DNA Inc., the sample tracking software company, today announced that ... joined STACS DNA as a Field Application Specialist. , “I am thrilled that ... of STACS DNA. “In further expanding our capacity as a scientific integrator, Hays brings ...
(Date:6/23/2016)... , June 23, 2016 On ... session at 4,833.32, down 0.22%; the Dow Jones Industrial Average ... 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ), Aralez ... Inc. (NASDAQ: BIND ). Learn more about these ...
Breaking Biology Technology: